Consequently, PD-L1 may be used as an independent prognostic factor and provide a theoretical basis for combining conventional therapy with immunotherapy targeting PD-L1 to reach better therapeutic effect in ESCC patients without esophagectomy. Here, CD274 is linked to esophageal squamous cell carcinoma.